<DOC>
	<DOCNO>NCT00988767</DOCNO>
	<brief_summary>The purpose study investigate whether HBV-DNA vaccination safe could restore immune response patient chronic hepatitis B non responder available therapy .</brief_summary>
	<brief_title>Safety Immunogenicity Naked DNA-based Vaccine Therapy Patients With Chronic Hepatitis B</brief_title>
	<detailed_description>- Despite availability effective hepatitis B vaccines many year , 370 million people remain persistently infect hepatitis B virus ( HBV ) . Persistent infection associate chronic liver disease lead development cirrhosis hepatocellular carcinoma patient . Viral persistence think related poor HBV-specific immune response . - Interferon ( IFN ) -alpha treatment significantly decrease HBV replication one third patient hepatitis B e antigen ( HBeAg ) -positive chronic active hepatitis B . Nucleoside analogue , lamivudine adefovir dipivoxil , inhibit HBV replication improve histological sign liver disease , use limit risk relapse treatment discontinuation emergence drug-resistant viral variant . - Patients acute self-limited hepatitis B display detectable polyclonal multispecific cytotoxic T lymphocyte T helper ( Th ) responses viral antigen , whereas response weak absent chronic HBV carrier . - Increasing strength HBV-specific T-cell response level find patient recover infection therefore goal treatment patient chronic hepatitis . - Immunization nucleic acid vaccine ( DNA vaccine ) usually elicit antibody response T lymphocytes Th1 cytokine profile . In animal model chronic hepatitis B infection , include nonhuman primate , intramuscular injection plasmid encode HBV envelope proteins induces rapid , strong , sustained humoral cell-mediated immune response . Clinical trial DNA vaccine hepatitis B conduct healthy adult volunteer use plasmid encode hepatitis B surface antigen gene gun delivery system show good tolerance . - We carry phase I trial HBV DNA vaccine patient chronic active viral hepatitis , aim restore HBV-specific immune response assess safety regard liver disease .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>chronic HBV carrier biopsy proven chronic hepatitis active HBV replication &gt; 6 month non respond Interferonalpha lamivudine treatment coinfection HIV , HCV , delta hepatitis virus alcohol consumption &gt; 40g/day decompensated liver disease HLA DR2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>DNA vaccine</keyword>
	<keyword>immunotherapy</keyword>
</DOC>